Saved To My Saved Content
Use BCG Answer to summarize this article

Are the stakeholders in Europe’s health care systems ready for a paradigm shift? Fueled in part by recent policy changes in the US, new pricing models for pharmaceuticals are prompting pharma companies, payers, and policymakers to rethink longstanding norms and models. Much more than pricing is at stake, and many topics are on the table, including patient access to treatment, as well as costs, value, business models, and innovation. Pharma companies, payers and policymakers, providers, and, of course, patients will feel the effects of the coming changes.

The US moves are the latest developments in a global reset of the pharma industry that stands to be a game changer for health care. Although the full extent of the changes remains to be determined, no one can afford to wait and see what plays out. Pricing pressure on new treatments could affect funding for innovation, patients’ access to care, and the sustainability of Europe’s health care systems. The strongest tendency for pharma companies, payers, and others will be to develop damage mitigation measures. But there is also an opportunity to reimagine how stakeholders can redesign the interconnections among prices, costs, innovation, and access to create a more balanced and patient-friendly system.

Here’s our assessment of the mechanisms at work and the strategic choices that lie ahead for Europe’s health care stakeholders.

Transatlantic Dynamics

The catalyst for the coming sea change, of course, is the US government’s switch to a pharmaceuticals pricing model based on the most-favored-nation (MFN) concept—the idea that US consumers and insurers should not pay more for drugs than consumers in other countries do. However, MFN is only the most recent development in a longer-term shift away from an unbalanced global system in which European markets, most of which have public-sector payers, have prioritized cost containment through centralized negotiation and international reference pricing, while the US operates under a multipayer system. US drug prices are, in most cases, from 100% to nearly 500% higher than those in Europe.

Incremental changes began earlier this decade. US government revisions to drug pricing standards under legislation passed in 2022 provided an early signal of sustained downward price pressure, marking a structural reset rather than a temporary policy shock. MFN intensifies existing price pressures by linking US drug prices to the lower end of prices in comparable international markets. Over the past year, prices and tariffs have been subject to negotiations with individual companies.

Although framed as a domestic reform, MFN fundamentally changes the role of the US in global pricing, connecting drug costs in the world’s largest pharma market much more closely to those in other countries. It strengthens international price linkages, because actions in one market spill over into others. Pharma companies are the first to feel the effects, with significant pressure on prices for new drugs (treatments within the same market should remain unaffected). Indeed, we estimate the profit impact on future launches at 25% to 70% of current levels, depending on which scenarios play out. (See Exhibit 1.)

Bar chart showing significant global EBITDA impact on pharma launches of MFN application to different US channels.

Pharma companies are already considering adjusting their pricing models, launch sequencing, and portfolio prioritization. The knock-on effects will impact not only drug costs but also patient access, innovation, fiscal sustainability, and policy. It’s becoming clear to European stakeholders that they can no longer address these issues in isolation. Manifestations of broader tension are apparent: while some markets (such as the UK) are adapting to sustain higher prices, others (such as Germany) are doubling down on cost containment. Uncoordinated actions could lead to systemic risks, including unavailable treatments, launch delays, and competitive disadvantage. European pharma CEOs are talking publicly about how MFN could cause companies to rethink launching new drugs in Europe to avoid lowering prices in the US.

Weekly Insights Subscription
Stay ahead with BCG insights on biopharma

Unattractive Options for Europe

The extent of the pressure in Europe will depend, in part, on whether MFN pricing in the US ultimately is applied in government insurance channels only or in private channels as well. Individual and confidential agreements between companies and the US government are determining this choice. Multiple scenarios are possible for pharma companies, and all are problematic. To optimize product launches for price, volume, access, and market uptake, companies can choose from three pricing approaches—or employ a combination—asset by asset: global price convergence, US–EU decoupling, and bifurcation. (See Exhibit 2.)

Bar chart and table showing the features and effects of three potential product launch strategies for pharmaceuticals.

Each launch strategy has financial ramifications, of course, with implications for the industrywide pool of funding available for continued innovation. Each strategy also affects payers and policymakers, which will foot the bill (with the specifics depending on their respective national health systems), as well as patients, who may encounter curtailed access to new treatments. Compounding the challenge for all participants is the fact that Europe is not one, but many, markets that are designed and act in different ways.

Global Price Convergence

Under this approach, pharma companies reduce US launch prices on selected assets so that they more closely match European levels. To mitigate value erosion, the companies increase prices where they can, although doing this will be complex and costly. Such price adjustments are the most direct and controllable way to combat MFN-driven pricing without reshaping the portfolio or the innovation strategy. They are most likely to succeed when applied to assets that address high unmet needs with limited or no established standards of care. Price convergence is also effective for assets whose pricing power is sustainable across markets and for those that have lower price differentials with MFN reference countries. Rare-disease treatments are an example.

There are a couple of significant differences between global price convergence and international reference pricing, under which a country determines the price of a drug, in part, on the basis of its price in a basket of reference countries. First, the US is usually not included in reference pricing because information on the prices paid is not always publicly available. Second, countries where a drug is more expensive don’t necessarily adapt its price downward following the reference check. Price differences in Europe are manageable in many cases, and volume in lower-price markets tends to be comparatively small. The current difference between prices in the US and Europe is multiples larger, and the volumes affected are extremely large.

Convergence will therefore have multiple potentially adverse knock-on effects. The global pool of funds available for investment in innovation is likely to decline significantly, as is pharma’s profitability. Payers in Europe could face increasing budget constraints, which could lead to more aggressive cost containment measures. Payers and policymakers may demand that pharma justify higher pricing by demonstrating a strong connection between innovation and value, such as by showing (though head-to-head trials, for example) that the clinical benefits of a drug are superior compared to those of other treatments. In addition, payers may introduce new pricing and risk-sharing models, such as tiered access or co-pays to manage increased costs, which could enable private payers to expand supplementary insurance. Ultimately, patients may suffer constrained and unequal access to some drugs as a result of tighter eligibility criteria and higher out-of-pocket payments for co-pays or supplementary insurance.

US–EU Decoupling

Alternatively, pharma companies may elect to forgo product launches in markets where the expected price would undermine global revenues by setting unattractively low reference points. Companies are most likely to adopt this approach toward assets with large price differences across countries (creating significant MFN exposure), assets with comparatively little differentiation vis-à-vis existing treatments, and assets targeting diseases that have established standards of care. Examples include modern treatments for diabetes and cardiovascular and respiratory conditions, and some oncology follow-on drugs or “me too” therapies. In a number of these therapeutic areas, companies already restrict launches to certain markets.

In instances where payers in most markets can’t meet US price levels, pharma companies can help protect US price levels by avoiding negative price comparisons. As a result, European patients will not have access to some new treatments, and funding for innovation will suffer from the absence of that revenue. Moreover, lack of access in certain markets will create the risk of reputational damage for pharma companies.

Bifurcation

A third way for pharma to draw a dividing line between the US and Europe is by pursuing tailored development, commercialization, and sourcing strategies for each market. Companies can optimize value across markets and sustain premium pricing by marketing differentiated treatments in the US while offering lower-priced drugs elsewhere. They can also develop new sources of innovative treatments. In China, for example, expertise and rates of innovation are on the rise.

This option is relevant for highly innovative assets with strong global potential and for assets with significant price differentials between the US and other markets. Examples include treatments for oncologic, immunologic, and central nervous system diseases, as well as certain specialty biologics with multiple indications.

Under bifurcation, the system becomes more complex and fragmented, but Europe maintains access to innovative assets. In the future, however, companies pursuing this option will have to move more quickly to bring innovations to market from countries other than the US—namely, from China. This will entail ensuring that the new assets meet European access requirements, which may require multiregional clinical trials, a reorganized value chain, and IP protections. Other factors include local bases for comparison and desired endpoints (such as quality of life), as well as access to data from more diverse patient populations.

Payers under this approach can expect to face increased complexity in assessing value while also potentially having to adapt frameworks for health technology assessment to multiple definitions of value. Pressure on regulatory alignment to determine acceptable evidence and localization requirements is likely to increase, too. Patients could end up using different drugs from different manufacturers in different countries, such as the US and China, to treat the same disease.

Difficult Choices for Payers and Policymakers

Pharma companies have been the first to act, and their decisions will have a direct and material impact on public payers (which will almost certainly feel strong pressure related to budgets and patient access) and on private payers (which may see opportunities to expand coverage). The impact on payers will vary according to which pricing strategies a pharma company employs for each asset. Global price convergence, for example, is likely to hit payer budgets hard. US–EU decoupling will have no impact on budgets but could dramatically affect patient access. Bifurcation will require a shift in how policymakers measure and assess drug effectiveness.

Three Options for Payers

Payers have three macro-options available: increase relative spending on innovation, expand total health care spending, and restrict access to innovation. (See Exhibit 3.) These are not mutually exclusive choices. Payers will likely deploy combinations of all three, depending on therapeutic area, patient population, and other factors.

Chart showing three potential mitigation measures for pharma payers and policymakers, with spending impact and rationale.

Increase relative spending on innovation. This option controls costs but does so at the cost of spending less on mature or outmoded products. Payers fund only true innovation, which raises the bar on demonstrating value upstream (for example, through a stringent framework for health technology assessment) and increases the focus on features that avoid downstream costs, such as hospitalization. The UK, for example, uses its QALY (quality-adjusted life years) metric, which combines quantity- and quality-of-life considerations into a single number, to determine whether a treatment provides value for money. Germany subjects new drugs to early-benefit assessments to justify their reimbursement prices.

By focusing on innovation, this approach reduces budgets for in-market drugs, especially comparable treatments, and for other aspects of care. The key is a tight focus on value delivered per health care dollar or euro spent, reducing expenditures on treatments that have been overtaken by new products. It reduces inpatient and outpatient reimbursement when innovation renders the cost unnecessary. Germany’s Pharmaceuticals Market Reorganization Act (known as AMNOG) requires drug manufacturers to demonstrate additional benefits over existing therapies and sets prices through negotiations with the federal body that represents the country’s statutory health and long-term care insurance funds.

Expand total health care spending. Increasing overall spending (whether it be government funded or patient funded) is rarely popular, but in many markets it may be less unpopular than reducing access to care, including innovative treatments. Payers can mitigate the impact of increased health care spending impact by using advanced pricing and risk-sharing models, such as value-based, population-based, and outcome-based pricing, tiered access, and co-pay models with patients or private payers. They can also look to private or individual financing to take on more of the cost, or they can implement “dread disease” or critical-illness provisions in insurance policies. And they can boost the amount of money flowing into the system by increasing premiums for public health insurance, one of the reforms currently under discussion in Germany. These moves can help maintain the current balance between cost and care delivery.

Shape access to innovation. Payers can manage patient pathways by prioritizing patients in the greatest need for access to high-cost treatments and by targeting downstream costs, such as hospitalization. The goals are to strengthen outcome- and indication-based reimbursement and to accelerate uptake of generics and biosimilars, using clinical guidelines and standards of care to steer prescribing.

A Changing Role for Policymakers

For their part, policymakers can enable regulations and inclusive frameworks that support innovative financing and equal access to treatments. They can work with the industry to develop clinical trials that better incorporate such factors as real-world evidence of improved outcomes and reduced costs.

In addition, policymakers can encourage the development and market entry of lower-cost alternative treatments. For example, they can harmonize clinical standards and trials for products from manufacturers in different counties (such as the US and China), and they can consider endorsing an EU industry policy that reinforces innovation and price flexibility.

But it is important not to lose sight of the long-term impact that these initiatives may have on the sustainability of the innovation ecosystem in their countries, including all the jobs—in R&D and manufacturing, among other areas—and value creation that come with it.

Next Steps for Stakeholders

However things play out, the changes will be far-reaching—and without prompt action by stakeholders, the impact on costs, access, and innovation may be significant. Pricing, innovation, and funding are not independent levers; they are tightly interconnected parts of a single system. Increasing funding for health care takes the pressure off pricing and maintains the investment pool for innovation, but at significant cost to taxpayers. Holding funding constant may entail making tradeoffs between pricing and innovation (as well as pharma companies and payers) when resources are capped.

Within each part of the ecosystem, stakeholders can take steps to improve their position in the emerging MFN-shaped reality. (See Exhibit 4.) The first step for pharma companies to take is to quickly assess their pipelines and the market-by-market pricing outlook for relevant drugs in both the US and Europe. Then they can identify which of the pricing strategies described above—global price convergence, US–EU decoupling, and bifurcation—hold the best prospects for each new asset. Manufacturers can also move toward more selective, value-driven innovation, prioritizing differentiated assets, strengthening clinical and real-world evidence generation, and focusing on the endpoints that matter most to patients and payers.

Diagram listing steps that pharma stakeholders can to improve their position in market shaped by MFN.

Payers can develop more flexible funding approaches, such as outcome-based agreements, staged or annuity payments, and dedicated funding mechanisms for high-cost therapies. Policymakers can explore ways to achieve more deliberate alignment of industry policy, R&D incentives, and pricing frameworks to ensure that Europe remains an attractive environment for high-value innovation while maintaining sustainable access.

Collaboration across the ecosystem is essential. Increasing funding, reducing prices, restricting innovation, and constraining access are fundamental interventions in a complex, multistakeholder system. The impacts are manageable only if all participants put the patient first and make a concerted effort to look at the issues from the perspective of every player. If they are to reach a balanced new equilibrium, all parties must come to the table firmly committed to thinking beyond current constraints and mechanisms. The changes underway are too big for marginal thinking, and they present an opportunity to build a better system. During the massive stress of the COVID-19 pandemic, the ecosystem came together and found solutions. There’s no reason it cannot do so again.

The authors are grateful to Cyril Dorlet, Claudia Leteneux-Pantais, and Michael Quigley for sharing their insights.